Abstract P737: Human Homologs Of Differentially Expressed Plasma MicroRNAs In Preclinical Murine Models Target Fundamental Mechanisms Of Cerebral Cavernous Malformation

Sharbel Romanos,Abhinav Srinath,Thomas Moore,Ying Li,Janne Koskimaki,Dongdong Zhang,Yan Li,Je Yeong Sone,Rhonda Lightle,Nick Hobson,Le Shen,Sara McCurdy,Abdallah Shkoukani,Agnieszka Stadnik,Kristina Piedad,Robert Shenkar,Miguel A Lopez-ramirez,Mark L Kahn,Douglas A Marchuk,Mark H Ginsberg,Romuald Girard,Issam A Awad

DOI: https://doi.org/10.1161/str.52.suppl_1.p737

IF: 10.17

2021-03-01

Stroke

Abstract:Introduction: There is a current need for sensitive and specific biomarkers of Cerebral Cavernous Malformation (CCM) that can be readily translated from preclinical to human models to accurately diagnose and monitor disease states and response to novel therapeutics. MiRNAs are small non-coding RNAs that influence gene expression and whose levels can be affected by disease states. We hypothesize that there are human homologs of differentially expressed (DE) miRNA in the plasma of CCM murine models that can be identified in CCM patients. We further hypothesize that these miRNAs have gene targets within previously published CCM transcriptomes, mechanistically linking them to CCM disease. Methods: Plasma miRNAs from homozygous and heterozygous Ccm1 and Ccm3 mice, as well as their respective wild type controls were sequenced and analyzed. Putative gene targets of DE miRNAs [p<0.05, false discovery rate (FDR) corrected] were queried in previously published mouse CCM transcriptomes. The human homologs of the DE miRNAs in the plasma of Ccm1 and Ccm3 mouse models were identified and assessed in the plasma of healthy controls (n=13), CCM1 (n=11), and CCM3 (n=11) patients using RT-qPCR. Results: 5 miRNAs in homozygous and 10 in heterozygous for Ccm1 , while 45 in homozygous and 2 in heterozygous for Ccm3 were DE in the plasma of mouse models (p<0.05, FDR corrected), had gene targets within CCM mouse transcriptomes, and have a human homolog. Preliminary results show mmu-miR-375-3p as DE in both Ccm1 +/- and Ccm3 -/- mice. RT-qPCR assays show that plasma relative quantification values of the human homolog hsa-miR-375-3p were higher in CCM3 than in CCM1 patients ( p <0.001) and in healthy controls ( p <0.05). Conclusion: DE plasma miRNAs identified in mouse models with human homologs and putative gene targets mechanistically implicated in CCM disease may be used as candidate biomarkers for specific clinical contexts.

peripheral vascular disease,clinical neurology